1829 – Anti-Müllerian hormone testing for identification of Polycystic Ovarian Morphology, to support the diagnosis of Polyendrocrine Metabolic Ovarian Syndrome (PMOS)

New Medicare Benefits Schedule item

Anti-Müllerian hormone (AMH) is made by small sacs in the ovaries called follicles. A laboratory test can measure AMH in a blood sample. People with polyendocrine metabolic ovarian syndrome (PMOS) may have higher AMH levels than expected for their age because they have many small, developing follicles. This is called polycystic ovarian morphology. It can also be identified using an internal ultrasound scan. Updated guidelines from 2023 include AMH testing as an alternative to ultrasound.

Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovarian syndrome or PCOS, affects up to 1 in 10 women of reproductive age. It can increase the risk of heart and metabolic diseases. PMOS can also affect fertility, reproductive health and mental wellbeing. 

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Friday 6 November 2026 11:59 pm AEDT
• Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 10 to 11 December 2026
• ESC meeting: To be confirmed
• MSAC meeting: To be confirmed

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.